FDA blocked melanoma drug as confusion reigned under Makary

Key Points:

• The FDA recently denied approval for RP1, a new melanoma treatment that extended life for about a third of clinical trial participants, causing disappointment among doctors and patients who viewed it as potentially life-saving for thousands.
• The FDA's rejection was influenced by concerns over the trial's design, particularly the lack of a control arm comparing RP1 with existing treatments, despite the manufacturer's argument that a control arm would be unethical.
• The decision reflects broader turmoil within the FDA under former commissioner Marty Makary, whose tenure was marked by political interference, inconsistent regulatory standards, and strained trust among industry and medical professionals.
• RP1's manufacturer, Replimune, is facing significant setbacks including staff layoffs and operational closures, raising doubts about the company's ability to continue development and complete ongoing trials.
• Critics argue the FDA's approach under Makary has created uncertainty around drug approval processes, impacting innovation and investment in treatments, while some experts suggest the accelerated approval pathway should allow more flexibility for promising therapies like RP1.